How a Common Sugar Substitute May Blunt Cancer Immunotherapy

If you or someone you love is on immunotherapy for cancer, you have probably already been told that gut health matters. What has been less clear is whether something as ordinary as a diet soda or a packet of yellow sweetener could be part of that picture. A new evidence review in Frontiers in Nutrition pulls together everything currently known, and not known, about one artificial sweetener, sucralose, and its possible link to how well checkpoint inhibitor immunotherapy works.

The review does not report new patient data itself. Instead, it organizes existing research, most centrally a 2025 clinical and laboratory study, into a hierarchy from strongest to weakest evidence, and it is explicit about where the science is solid and where it is still just a lead worth chasing.

Key takeaways:

• A 2025 study found that cancer patients with higher self-reported sucralose intake had lower odds of responding to anti-PD-1 immunotherapy and shorter progression-free survival, most clearly in advanced melanoma and non-small cell lung cancer.
• In mice, sucralose altered gut bacteria in a way that depleted arginine, an amino acid T cells need to function, and this partly explains a weaker immunotherapy response, an effect that could be reversed with arginine or citrulline supplementation.
• The human findings are observational and based on one study cohort, self-reported diet, and no biomarker confirmation, so they are not proof that cutting sucralose will improve treatment outcomes.
• Researchers say there is no basis yet to tell patients to stop using sucralose, and swapping it for sugar is not an established alternative either.

Higher Sucralose Intake Tied to Weaker Anti-PD-1 Response

The clearest human evidence comes from a study by Morder and colleagues, published in Cancer Discovery in 2025, and cited throughout this Frontiers in Nutrition review as the single study anchoring the entire field. That study followed 132 patients with advanced cancer, 91 with melanoma and 41 with non-small cell lung cancer (NSCLC), all treated with anti-PD-1-based immunotherapy or chemoimmunotherapy. Patients reported their diet before starting treatment using a validated tool called the Diet History Questionnaire III, and researchers split them by a data-derived cutoff of more than 0.16 milligrams of sucralose per kilogram of body weight per day, roughly the amount in one sweetener packet for an average adult.

In the melanoma group, higher sucralose intake was independently linked to lower odds of the tumor responding to treatment (multivariable odds ratio 0.28, meaning roughly a 72 percent lower likelihood of response after adjusting for other factors) and to worse progression-free survival (multivariable hazard ratio 2.91, meaning nearly three times the risk of the cancer progressing or the patient dying during the study period). In the NSCLC group, higher intake was tied to a significantly lower response rate and shorter progression-free survival as well. A separate, smaller cohort of 25 patients with high-risk resectable melanoma, treated before surgery with a nivolumab-based immunotherapy combination, showed the same pattern: higher sucralose intake tracked with a lower rate of major pathologic response and shorter relapse-free survival.

Why Cancer Patients on Immunotherapy Should Pay Attention

Checkpoint inhibitors like anti-PD-1 drugs have become a backbone of treatment for melanoma, NSCLC, and a growing list of other solid tumors, but a meaningful share of patients do not respond, or respond and then relapse. Doctors already know that antibiotics, proton pump inhibitors, and broad dietary patterns can shift gut bacteria in ways that affect how well these drugs work. This review adds sucralose, found in diet sodas, many "sugar-free" products, and some medication formulations, to the list of exposures worth asking about, though it stops well short of calling it an established risk factor. For someone actively weighing treatment options or trying to understand why a drug worked well for one person and not another, this is a plausible piece of the puzzle rather than a settled answer.

How the Evidence Was Weighed, From Mouse Models to Patients

This review's own methodology is part of the story. The authors searched PubMed, Embase, and the Web of Science Core Collection from the start of each database through 17 July 2026, and sorted everything they found into five tiers based on how directly it addresses the question, from tier 1 (direct human data on sweeteners and immunotherapy outcomes) down to tier 5 (cell-based mechanistic experiments). By that framework, only the Morder study qualifies as direct clinical evidence; everything else, including dozens of studies on how sweeteners affect the gut microbiome (the community of bacteria and other microbes living in the intestines) in general, is contextual or mechanistic support.

The mechanistic backbone comes largely from mouse experiments in that same study. Mice given sucralose in their drinking water for two weeks before tumors were implanted, and continuously afterward, showed impaired anti-PD-1 responses. Depleting the animals' gut bacteria with antibiotics, and separately transferring gut bacteria between mice, confirmed that the effect ran through the microbiome (the resident population of gut bacteria) rather than being a direct drug interaction. The mechanism traced to arginine, an amino acid immune T cells rely on for energy and function; sucralose exposure was linked to lower microbiota-accessible arginine, which impaired T-cell metabolic fitness. Critically, giving the mice supplemental arginine or citrulline, or transferring in gut bacteria from mice that had responded well to treatment, restored both T-cell function and the response to anti-PD-1 therapy. Separately, other lab work found that sucralose can directly dampen T-cell activity even without involving gut bacteria at all, an effect not seen with two other common sweeteners, acesulfame potassium and saccharin, at comparable doses.

What This Means if You or a Loved One Is on Immunotherapy

Nothing in this review supports stopping sucralose on your own or swapping it for sugar, which carries its own downsides for blood sugar control and overall diet quality. The review's authors are explicit that current evidence does not justify telling patients to change their sweetener use, precisely because the clinical signal comes from one observational study using self-reported diet, not a controlled trial. What it does support is a conversation. If you are undergoing checkpoint inhibitor treatment and use sucralose-sweetened products regularly, mentioning that habitual intake to your oncology team, along with your broader diet and fiber intake, is a reasonable thing to raise, especially if you are also considering an oncology dietitian consult. This is information worth having on the table, not an instruction to act on unilaterally.

Why This Isn't Proof Yet

The human data has real limits. Diet was self-reported rather than measured with a biomarker, the sucralose-intake cutoff was derived from this specific dataset rather than set in advance, and the study drew from a single registry with a fairly narrow mix of tumor types. Confounding is also a live concern: factors like fiber intake, overall diet quality, disease severity, and other medications could influence both a patient's sucralose habits and their treatment response independent of any biological effect. The review's authors state plainly that this entire clinical model rests on one publication, without independent replication in a separate patient group. Mouse experiments, while mechanistically informative, do not translate directly to humans because of differences in gut bacteria, diet, and physiology between mice and people.

What Comes Next for This Research

The review calls for prospective studies that measure sucralose exposure with urine or blood biomarkers rather than diet questionnaires alone, paired with detailed gut microbiome, metabolite, and immune profiling, in new patient cohorts. It also flags open questions the field has barely touched: whether the effect differs by sex, whether other sweeteners carry similar risks through different mechanisms, and whether arginine or citrulline supplementation could someday help patients who cannot easily cut sucralose from their diet. None of that groundwork exists yet.

Common Questions

Does this mean I should stop using sucralose if I'm on immunotherapy? No. The researchers explicitly say current evidence does not support changing sucralose use, and switching to sugar is not a proven safer alternative; talk to your oncology team about your overall diet instead of making a unilateral change.

Is this study about sucralose specifically, or all artificial sweeteners? It is centered on sucralose. Two other sweeteners tested in lab experiments, acesulfame potassium and saccharin, did not reproduce the same direct effect on T cells at comparable doses, and evidence for sweeteners besides sucralose is much thinner.

How much sucralose intake counts as "higher" in this research? The study used a data-derived threshold of more than 0.16 milligrams per kilogram of body weight per day, roughly one sweetener packet daily for an average-sized adult, though this cutoff came from the study's own data rather than a preset clinical guideline.

Could gut bacteria supplements or diet changes counteract this effect? In mice, restoring gut bacteria from good responders, or supplementing with the amino acids arginine or citrulline, reversed the impaired immune response, but this has not been tested in humans and is not an established treatment.

References

Jie Li, Deng-Hua Li, Yu-Hao Liu, et al. (2026). Non-nutritive sweeteners, the gut microbiome, and tumor immunity: evidence hierarchy and a sucralose-centered translational model. Frontiers in Nutrition. https://doi.org/10.3389/fnut.2026.1868431